BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting rights attached to shares and 166,184 equivalent financial instruments in Fagron. This change was reported under Belgian transparency rules and reflects BlackRock's adjusted position in the pharmaceutical compounding company. Investors should monitor further disclosures for any changes in BlackRock's holdings.
BlackRock, Inc.'s recent shareholding adjustment in Fagron NV is presented here alongside Pluang's health sector market data for context. For readers following health stocks, 36 out of 150 US health-sector stocks rose while 114 fell as of Oct 16, 2026 23:21 WIB. Notable movers include DNA at USD 10.35 with a 1-day change of -11.99%, Moderna at USD 213.22 down 9.84%, and Erasca at USD 13.45 down 9.55%.
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
Meridian International Center announced its inaugural New Architects of American Influence cohort, recognizing 25 leaders from business, technology, culture, sports, and government who are shaping U.S. global influence. The 2026 cohort includes leade...
M&T Bank reported adjusted earnings per share of $5.08 and revenue of $2.55 billion for Q3 2026, both surpassing analyst estimates. This marks the fourth consecutive quarter the bank has exceeded earnings and revenue expectations, reflecting consiste...
